Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation
Cetin, Arif E.
Stevens, Mark M.
Calistri, Nicholas L.
Kimmerling, Robert J.
Manalis, Scott R.
MetadataShow full item record
CitationCetin, Arif E., Mark M. Stevens, Nicholas L. Calistri, Mariateresa Fulciniti, Selim Olcum, Robert J. Kimmerling, Nikhil C. Munshi, and Scott R. Manalis. 2017. “Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation.” Nature Communications 8 (1): 1613. doi:10.1038/s41467-017-01593-2. http://dx.doi.org/10.1038/s41467-017-01593-2.
AbstractMultiple myeloma (MM) has benefited from significant advancements in treatment that have improved outcomes and reduced morbidity. However, the disease remains incurable and is characterized by high rates of drug resistance and relapse. Consequently, methods to select the most efficacious therapy are of great interest. Here we utilize a functional assay to assess the ex vivo drug sensitivity of single multiple myeloma cells based on measuring their mass accumulation rate (MAR). We show that MAR accurately and rapidly defines therapeutic susceptibility across human multiple myeloma cell lines to a gamut of standard-of-care therapies. Finally, we demonstrate that our MAR assay, without the need for extended culture ex vivo, correctly defines the response of nine patients to standard-of-care drugs according to their clinical diagnoses. This data highlights the MAR assay in both research and clinical applications as a promising tool for predicting therapeutic response using clinical samples.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:34493096
- HMS Scholarly Articles